Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.